SI-BONE, Inc.
NASDAQ:SIBNMedical - Devices
+$0.53 today
- Market cap
- $1.06B
- Beta
- 0.70
- P/E (TTM)
- -41.4
- EPS (TTM)
- -$0.38
Volume 1.12M
Average 0.68M
SIBN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
SI-BONE, Inc.NASDAQ: SIBN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $4.19M fell 7.5% year over year, behind the +2.1% change in trailing-twelve-month research & development. Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.
Context
- Research & development amounted to 8.7% of revenue in FY2025, down 1.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -7.5% toward the trailing-twelve-month pace of +2.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 17.45M USD
- Year-over-year change
- +5.4%
- 4-year CAGR
- +8.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.45M | +5.4% |
| FY2024 | 2024-12-31 | 16.56M | +10.2% |
| FY2023 | 2023-12-31 | 15.03M | +10.3% |
| FY2022 | 2022-12-31 | 13.63M | +9.5% |
| FY2021 | 2021-12-31 | 12.44M | — |
Research & Development vs competitors
How SIBN compares with its peers on the latest reported figures
- SIBN's LTM Mar 2026 research & development of $17.11M is the lowest of the 6 companies compared; the peer median is $184.82M.
- Its year-over-year change of +2.1% is the 4th highest of 6, against a peer median of +10.1%.
- Research & development amounts to 8.3% of revenue for SIBN, versus a peer median of 5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.66B | +10.1% | +8.8% | 6.4% | |
| FY2025 | $346M | +0.9% | +0.1% | 5.6% | |
| LTM Jun 2026 | $184.82M | +30.3% | +36.3% | 5.9% | |
| LTM Mar 2026 | $77.25M | -2.6% | +20.1% | 9.8% | |
| LTM Mar 2026 | $59.27M | +10.2% | +5.8% | 4.3% | |
| LTM Mar 2026 | $17.11M | +2.1% | +8.6% | 8.3% | |
| Peer median (excluding SIBN) | $184.82M | +10.1% | +8.8% | 5.9% | |
Competitors are the stored peer set for SIBN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 90.15M | 106.41M | 138.89M | 167.18M | 200.93M |
| Cost of Revenue | 10.43M | 15.71M | 29.47M | 35.06M | 41.05M |
| Gross Profit | 79.72M | 90.7M | 109.42M | 132.12M | 159.88M |
| Gross Margin | 88.4% | 85.2% | 78.8% | 79.0% | 79.6% |
| Research & Development | 12.44M | 13.63M | 15.03M | 16.56M | 17.45M |
| Selling, General & Admin | 118.95M | 136.69M | 141.32M | 150.81M | 164.76M |
| Operating Expenses | 131.39M | 150.31M | 156.35M | 167.37M | 182.21M |
| Depreciation & Amortization | 2.09M | 3.45M | 5.43M | 4.38M | 2.72M |
| EBITDA | (50.97M) | (54.99M) | (34.45M) | (23.09M) | (10.91M) |
| EBITDA Margin | -56.5% | -51.7% | -24.8% | -13.8% | -5.4% |
| Operating Income | (51.67M) | (59.61M) | (46.93M) | (35.25M) | (22.33M) |
| Operating Margin | -57.3% | -56.0% | -33.8% | -21.1% | -11.1% |
| Interest Income | 186K | 1.3M | 6.92M | 7.85M | 6.07M |
| Interest Expense | 5.37M | 2.82M | 3.46M | 3.44M | 5.28M |
| Other Income / Expenses | (4.9M) | (1.65M) | 3.6M | 4.34M | 3.42M |
| Income Before Tax | (56.57M) | (61.26M) | (43.34M) | (30.91M) | (18.91M) |
| Pre-Tax Margin | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (56.57M) | (61.26M) | (43.34M) | (30.91M) | (18.91M) |
| Net Margin | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% |
| EPS (Basic) | (1.71) | (1.79) | (1.13) | (0.75) | (0.44) |
| EPS (Diluted) | (1.71) | (1.79) | (1.13) | (0.75) | (0.44) |
| Weighted Avg Shares | 33.15M | 34.2M | 38.43M | 41.47M | 43.51M |
| Weighted Avg Shares (Diluted) | 33.15M | 34.2M | 38.43M | 41.47M | 43.51M |
SI-BONE, Inc.
NASDAQ:SIBN
Intrinsic Alpha fair value
Locked
Current Price
$23.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.